Lista de obras - Nicola Personeni - Dominio Público Uruguay

A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma

artículo científico publicado en 2013

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

artículo científico publicado en 2014

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

artículo científico publicado en 2007

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

artículo científico publicado en 2010

Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough?

scientific article published on 23 May 2011

Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

artículo científico publicado en 2018

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

artículo científico publicado en 2016

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options

artículo científico publicado en 2020

Biomarkers in Hepatocellular Carcinoma--Letter

scientific article published on 02 August 2012

Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.

artículo científico publicado en 2016

Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.

artículo científico publicado en 2017

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

artículo científico publicado en 2005

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

artículo científico publicado en 2018

Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

artículo científico publicado en 2015

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study

scientific article published on 21 March 2018

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

artículo científico publicado en 2018

Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?

artículo científico publicado en 2006

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

scientific article published on 01 April 2006

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.

artículo científico publicado en 2015

Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection

scientific article published on 20 June 2011

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma ⬇️

artículo científico publicado el 25 de octubre de 2003

Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipies

artículo científico publicado en 2006

Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies

artículo científico publicado en 2017

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

scientific article published on 10 July 2020

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

artículo científico publicado en 2001

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

artículo científico publicado en 2015

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

artículo científico publicado en 2007

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

article

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

artículo científico publicado en 2013

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

artículo científico publicado en 2021

Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?

scientific article published on 01 March 2007

PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA).

artículo científico publicado en 2016

Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy

artículo científico publicado en 2010

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

artículo científico publicado en 2017

Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?

artículo científico publicado en 2018

Regorafenib for the treatment of unresectable hepatocellular carcinoma.

artículo científico

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

artículo científico publicado en 2018

SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS

scientific article published on 25 November 2020

Shaping the landscape of immune oncology in hepatocellular carcinoma

artículo científico publicado en 2018

Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!

artículo científico publicado en 2017

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

artículo científico publicado en 2011

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach

artículo científico publicado en 2014

The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine

artículo científico publicado en 2019

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.

artículo científico publicado en 2012

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

article

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

artículo científico publicado en 2012

Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma

artículo científico publicado en 2013

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

artículo científico publicado en 2016

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

artículo científico publicado en 2012

Lista de obras de Nicola Personeni

A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

Advanced colorectal liver metastases and surgery after preoperative chemotherapy: is response-based selection enough?

Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases.

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options

Biomarkers in Hepatocellular Carcinoma--Letter

Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.

Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.

Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection

HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma ⬇️

Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipies

Hepatocellular Carcinoma: A Global Disease in Need of Individualized Treatment Strategies

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?

PD-019ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA).

Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?

Regorafenib for the treatment of unresectable hepatocellular carcinoma.

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.

SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS

Shaping the landscape of immune oncology in hepatocellular carcinoma

Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach

The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.